Market Overview

HemaCare Details Expanded GMP Capabilities at CAR-TCR Summit in Boston, MA.

Share:

Facility Relocation and Expansion Offers Fully-Integrated GMP Cell
Therapy Services

HemaCare
Corporation
(OTC:HEMA), a global leader in the customization of
human-derived biological products and services for biomedical research
and cell therapy, today announces details of their expanded GMP
capabilities at the annual CAR-TCR Summit on September 4-7, 2018.
HemaCare will be relocating its operations and corporate headquarters to
a larger, state-of-the-art facility with four GMP cleanrooms for
expansion of GMP-compliant cells, tissues, and services. This new center
of excellence will make HemaCare the first commercial provider of GMP
human primary cells isolated from leukopaks collected onsite. These
services will support the research, scientific, and clinical community
by providing high-quality GMP cells in a reproducible manner which
comply with both FDA and European Medicines Agency (EMA) regulations.

"Attending the CAR-TCR conference allows HemaCare the opportunity to
reveal some of the future GMP capabilities debuting in 2018. We are
excited by the overall growth of the cell therapy industry, and we have
strategically expanded our capabilities to meet industry demand and
continue to provide high-quality starting material to the leading cell
and gene therapy companies in the world," said Pete van der Wal,
HemaCare's President and CEO.

HemaCare's GMP-compliant clean rooms will allow the following services
to be performed onsite: collection, processing and isolation of GMP raw
material and cells, processing of autologous patient material, and
GMP-compliant cryopreservation and storage at the new biobanking
facility. Flexible production environments and optimized process flow
will enable HemaCare to address customers' increasingly complex
requirements and provide sufficient scalability to support their global
customer base. GMP apheresis collection starting material from
HemaCare's extensive registry of recallable, reliable donors can be
cryopreserved and shipped as needed for allogeneic cell therapy
manufacturing allowing HemaCare to expand upon its recently launched
unique cryopreserved leukopak offering.

"CAR-TCR Summit offers us an ideal opportunity to stay informed on the
latest developments regarding T cell therapies. We look forward to
meeting with our industry partners and cell therapy development
customers to discuss current challenges in the industry. As a company,
we hope to address many of these hurdles with our products and services
offered from our new GMP facility," said Dr. Dominic Clarke, HemaCare's
Global Head of Cell Therapy.

The 40,000-square foot facility will be located on an expansive
corporate campus in the nearby San Fernando Valley, California.

For more information about HemaCare, please contact Lou Juliano at ljuliano@hemacare.com
or visit us at booth #5 at the CAR-TCR
Summit
.

About HemaCare

HemaCare is a global leader in the customization of human-derived
biological products and services for biomedical research, drug discovery
and cellular therapy process development. The company's network of
FDA-registered, GMP/GTP-compliant collection centers ensure fresh donor
material is available to customers and for use within HemaCare's
isolation laboratory. Human biological material including peripheral
blood, bone marrow, and cord blood is isolated into various primary
cells types for fresh and frozen distribution. For 40 years, HemaCare
has developed an extensive registry of repeat donors and provides
human-derived primary blood cells and tissues for biomedical and drug
discovery research and cell therapy clinical trials, and supports
commercialization with apheresis collections, directly enabling
customers to advance both autologous and allogeneic cellular therapies.

For more information, please visit www.hemacare.com.

View Comments and Join the Discussion!